IO Biotech(IOBT) - 2024 Q2 - Quarterly Results

Exhibit 99.1 IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights • Phase 3 interim analysis outcome still expected in Q3 2024 for the overall response rate (ORR) in the pivotal trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced melanoma; outcome of primary endpoint of progression free survival (PFS) expected in first half of 2025 • Compl ...